News Release

<< Back

  View printer-friendly version

Teleflex Receives Innovative Technology Designation from Vizient for LMA® Gastro™ Airway

Designation recognizes products that bring improvements to the health care industry

WAYNE, Pa.--(BUSINESS WIRE)--Nov. 7, 2017-- Teleflex Incorporated (NYSE: TFX) announced its LMA® Gastro™ Airway has received a 2017 Innovative Technology designation from Vizient, Inc., the largest member-driven health care performance improvement company in the country. The designation was based on direct feedback from hospital experts who interacted with LMA® Gastro™ Airway at the Vizient Innovative Technology Exchange in Denver on Sept. 14, 2017.

The LMA® Gastro™ Airway from Teleflex is the first laryngeal mask specifically designed to enable clinicians to proactively manage their patients’ airways while facilitating direct endoscopic access via the integrated channel. With the airway in place, clinicians can easily direct an endoscope and provide a patent airway for patient safety, which can facilitate monitoring of end tidal CO2.

The use of moderate-to-deep sedation during endoscopy is a common practice. Respiratory depression from sedative drugs and airway obstruction requiring intervention are known risks associated with endoscopic procedures, with studies demonstrating that hypoxemia can occur in 11-50% of cases.1-3 In the United States there are more than 6.9 million upper endoscopies performed each year.4 Today, many of these are undertaken without an airway management device in place.

“Teleflex continues to develop innovative airway management products through collaboration with clinicians around the world. The introduction of LMA® Gastro™ provides a controlled airway management solution for many higher risk patients undergoing routine upper GI procedures,” said Justin McMurray, President and General Manager, Teleflex Anesthesia and Emergency Medicine Division. “We are honored to have the LMA® Gastro™ Airway recognized as innovative technology by Vizient and look forward to a continued relationship with Vizient and clinicians with a focus on advancing clinical practice.”

“The Vizient Innovative Technology Exchange offers medical technology suppliers the opportunity to demonstrate their products and gain direct feedback from the approximately 1,500 clinical experts who attend the event. Following exploration of the technological capabilities of the LMA® Gastro™ Airway at the Exchange, attendees recommended it receive an Innovative Technology designation. Congratulations to Teleflex on receiving this status,” said Debbie Archer, director of procurement and Vizient Innovative Technology Program leader.

Vizient represents a diverse membership base that includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and non-acute health care providers, with more than $100 billion in annual purchasing volume. Through its Innovative Technology Program, Vizient works with member-led councils and task forces to review potentially innovative products. If it is determined that a product is innovative, Vizient may award a contract outside of the competitive bid cycle.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people's lives. We apply purpose-driven innovation - a relentless pursuit of identifying unmet clinical needs - to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rüsch® and Weck® - trusted brands united by a common sense of purpose.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

Teleflex, the Teleflex logo, Cuff Pilot, Deknatel, Hudson RCI, LMA, LMA Gastro, Pilling, Rüsch, and Weck are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries.

© 2017 Teleflex Incorporated. All rights reserved. MC-003914

References

  1. Cote GA, Hovis RM, Ansstas MA, et al. Incidence of sedation-related complications with Propofol use during advanced endoscopic procedures. Clin Gastroenterol Hepatol. 2010;8(2):137-142.
  2. Qadeer MA, Rocio Lopez A, Dumot JA, Vargo JJ. Risk factors for hypoxemia during ambulatory gastrointestinal endoscopy in ASA I-II patients. Dig Dis Sci. 2009;54(5):1035-1040.
  3. de Paulo GA, Martins FP, Macedo EP, Goncalves ME, Mourao CA, Ferrari AP. Sedation in gastrointestinal endoscopy: a prospective study comparing nonanesthesiologist-administered Propofol and monitored anesthesia care. Endosc Int Open. 2015;3(1):E7-E13.
  4. Peery AF, Dellon ES, Lund J, et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology. 2012;143(5):1179-1187 e1171-1173.

Source: Teleflex Incorporated

Teleflex Incorporated
Jake Elguicze
Treasurer and Vice President, Investor Relations
610-948-2836